Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients-Reference-Cited by-同舟云学术

Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients

Published:2014-04-29 Issue:3 Volume:36 Page:224-236
ISSN:0892-3973
Container-title:Immunopharmacology and Immunotoxicology
language:en
Short-container-title:Immunopharmacology and Immunotoxicology

Author:

Kawano Kouichiro,Tsuda Naotake,Matsueda Satoko,Sasada Tetsuro,Watanabe Noriko,Ushijima Kimio,Yamaguchi Tomohiko,Yokomine Masato,Itoh Kyogo,Yamada Akira,Kamura Toshiharu

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine,Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.3109/08923973.2014.913617

Reference33 articles.

1. Cancer Statistics, 2009

2. Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

3. Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer

4. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nucleic acid‐based vaccine for ovarian cancer cells; bench to bedside;Cell Biochemistry and Function;2024-03

2. Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape;Pharmaceuticals;2023-07-24

3. Immunotherapy in gynecologic malignancies;DiSaia and Creasman Clinical Gynecologic Oncology;2023

4. Plasma level of prostate related‑antigen peptide‑reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines;Experimental and Therapeutic Medicine;2021-06-25

5. Immuno-Oncology for Gynecologic Malignancies;Advances in Experimental Medicine and Biology;2021